General Information

This workshop will build on the momentum begun with the first workshop held in September 2008 (http://meetings.nigms.nih.gov/?ID=3447).  It is intended to bring together researchers in pharmacology, pharmacokinetics/pharmacodynamics, systems biology, computer modeling and related areas with a focus on how systems biology is contributing to drug discovery and understanding drug action now and in the future.  For the purpose of this meeting we propose a working definition of quantitative and systems pharmacology:

An emerging discipline that aims to discover and understand therapeutic molecules at the levels of target engagement, changes in cellular biochemistry, impact on human pathophysiology and optimal clinical use. Quantitative and systems pharmacology aims to guide drug discovery and clinical development by developing formal mathematical models that incorporate data at multiple temporal and spatial scales and link disciplines that include chemical biology, molecular genetics and genomics, pathophysiology, applied mathematics, and medicine. Systems pharmacological studies are distinguished not only by their quantitative, model-driven nature, but also by their focus on dynamic interactions among individual elements.  Systems pharmacology explicitly seeks to incorporate classical approaches from physiology, pharmacology and cell biology and is not limited to “omics” and bioinformatic analysis. Success in quantitative and systems pharmacology approaches will make it possible to discover and design better drugs, predict patient-specific responses to therapy and ultimately improve clinical outcomes.
 
Through state-the-art-talks, presentations of perspectives, panel discussions, and poster presentations, answers to the following specific questions will be sought:
1.       Can we articulate a vision of the impact of systems pharmacology over the next decade?
2.      What is the state-of-the-art in quantitative and systems pharmacology and who and what are key intellectual drivers?
3.      How should balance be achieved between integration across spatial and temporal scales and better understanding of individual scales (i) from molecules to cells to organisms and (ii) from rapid biochemical transformations to much slower disease processes?
4.      How can research and educational links be strengthened between computational and experimental approaches and between basic and clinical research?
5.      What elements must be in place for successful development of quantitative and systems pharmacology - what gaps exist and how should they be addressed?

Version: 2.1.0